Skip to main content
Terug
STOK logo

Stoke Therapeutics, Inc.

Datakwaliteit: 100%
STOK
NASDAQ Healthcare Biotechnology
€ 32,18
▼ € 1,22 (-3,65%)
Marktkapitalisatie: 1,90B
Dagbereik
€ 31,85 € 33,93
52-Weeksbereik
€ 5,35 € 40,22
Volume
409.419
50D / 200D Gem.
€ 32,73 / € 24,99
Vorige Slotkoers
€ 33,40

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -276,5 0,3
P/B 5,4 2,9
ROE % -2,4 3,7
Net Margin % -3,7 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 42,75 +32.8%
Low: € 35,00 High: € 60,00
Forward WPA
-€ 3,38
Omzet Sch.
27 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 0,08
€ 0,00 – € 0,18
340 M 6
FY2028 -€ 2,15
-€ 3,43 – -€ 0,69
120 M 8
FY2027 -€ 3,16
-€ 3,77 – -€ 2,05
49 M 9

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Generating 44,92M in free cash flow
Capital efficient — spends only 0,36% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)404,50%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-2,37%
ROIC-4,38%
Net Margin-3,73%
Op. Margin-11,16%

Veiligheid

Debt / Equity
0,00
Current Ratio5,28
Interest Coverage-1,50

Waardering

P/E Ratio
-276,47
P/B Ratio5,40
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 404,50% Revenue Growth (3Y) 358,31%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 184,42M Net Income (TTM) -6,89M
ROE -2,37% ROA -1,65%
Gross Margin 100,00% Operating Margin -11,16%
Net Margin -3,73% Free Cash Flow (TTM) 44,92M
ROIC -4,38% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 5,28
Interest Coverage -1,50 Dividend Yield 0,00%
Valuation
P/E Ratio -276,47 P/B Ratio 5,40
P/S Ratio 10,32 PEG Ratio 2,94
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,90B Enterprise Value 1,82B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 184,42M 36,56M 8,78M 12,41M 0,0
Net Income -6,89M -88,98M -104,70M -101,07M -85,81M
EPS (Diluted) -0,12 -1,65 -2,38 -2,60 -2,34
Gross Profit 184,42M 36,56M 8,78M 12,41M 0,0
Operating Income -20,59M -101,37M -114,77M -104,36M -86,07M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 418,43M 271,56M 228,34M 256,07M 238,87M
Total Liabilities 65,98M 42,53M 68,78M 71,22M 21,09M
Shareholders' Equity 352,46M 229,02M 159,57M 184,85M 217,78M
Total Debt 0,0 2,32M 2,06M 2,36M 1,51M
Cash & Equivalents 84,22M 127,98M 191,44M 113,56M 144,90M
Current Assets 305,70M 232,76M 215,34M 244,07M 229,22M
Current Liabilities 57,88M 40,06M 30,82M 31,39M 17,14M